Baltzer WI et al. |
Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. |
2006 |
Am. J. Vet. Res. |
pmid:16426215
|
Faraday N et al. |
Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. |
2006 |
Am. J. Cardiol. |
pmid:16950183
|
Renda G et al. |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. |
2006 |
Clin. Pharmacol. Ther. |
pmid:16952493
|
Markuszewski L et al. |
Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? |
2006 |
Basic Clin. Pharmacol. Toxicol. |
pmid:16635110
|
Laleman W et al. |
A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. |
2006 |
Eur. J. Clin. Invest. |
pmid:16620286
|
Ohmori T et al. |
Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. |
2006 |
J. Thromb. Haemost. |
pmid:16706971
|
Santilli F et al. |
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. |
2006 |
J. Am. Coll. Cardiol. |
pmid:16412866
|
Kataoka M et al. |
A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. |
2005 |
Am. J. Respir. Crit. Care Med. |
pmid:16192456
|
Gonzalez-Conejero R et al. |
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? |
2005 |
Stroke |
pmid:15604423
|
Falco A et al. |
Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. |
2005 |
Atherosclerosis |
pmid:16285996
|